Nuvalent (NUVL) Competitors

$99.90 -2.40 (-2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$98.30 -1.60 (-1.61%)

As of 05:25 PM Eastern

NUVL vs. RVMD, INSM, BNTX, ROIV, and MRNA

Should you buy Nuvalent stock or one of its competitors? MarketBeat compares Nuvalent with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvalent include Revolution Medicines (RVMD), Insmed (INSM), BioNTech (BNTX), Roivant Sciences (ROIV), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Nuvalent compare to Revolution Medicines?

Nuvalent (NASDAQ:NUVL) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Nuvalent has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Revolution Medicines	$11.58M	2,650.52	-$1.13B	-$7.07	N/A

In the previous week, Nuvalent had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 13 mentions for Nuvalent and 6 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.78 beat Nuvalent's score of 0.05 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Nuvalent's return on equity of -40.11% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Revolution Medicines	N/A	-83.22%	-59.06%

Nuvalent presently has a consensus target price of $137.25, suggesting a potential upside of 37.39%. Revolution Medicines has a consensus target price of $108.88, suggesting a potential downside of 24.59%. Given Nuvalent's higher possible upside, analysts clearly believe Nuvalent is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 5.0% of Nuvalent shares are held by insiders. Comparatively, 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nuvalent has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Summary

Nuvalent beats Revolution Medicines on 8 of the 14 factors compared between the two stocks.

How does Nuvalent compare to Insmed?

Insmed (NASDAQ:INSM) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Insmed has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Insmed currently has a consensus price target of $210.95, suggesting a potential upside of 96.88%. Nuvalent has a consensus price target of $137.25, suggesting a potential upside of 37.39%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Insmed had 8 more articles in the media than Nuvalent. MarketBeat recorded 21 mentions for Insmed and 13 mentions for Nuvalent. Insmed's average media sentiment score of 0.68 beat Nuvalent's score of 0.05 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvalent has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	38.30	-$1.28B	-$5.75	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

97.3% of Nuvalent shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nuvalent has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Nuvalent's return on equity of -40.11% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Nuvalent	N/A	-40.11%	-35.43%

Summary

Insmed and Nuvalent tied by winning 8 of the 16 factors compared between the two stocks.

How does Nuvalent compare to BioNTech?

Nuvalent (NASDAQ:NUVL) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Nuvalent has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvalent presently has a consensus target price of $137.25, indicating a potential upside of 37.39%. BioNTech has a consensus target price of $130.60, indicating a potential upside of 46.99%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

In the previous week, Nuvalent had 5 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for Nuvalent and 8 mentions for BioNTech. BioNTech's average media sentiment score of 0.12 beat Nuvalent's score of 0.05 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvalent has higher earnings, but lower revenue than BioNTech. Nuvalent is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
BioNTech	$3.25B	6.92	-$1.29B	-$5.88	N/A

Nuvalent has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

BioNTech beats Nuvalent on 10 of the 16 factors compared between the two stocks.

How does Nuvalent compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Nuvalent had 10 more articles in the media than Roivant Sciences. MarketBeat recorded 13 mentions for Nuvalent and 3 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.37 beat Nuvalent's score of 0.05 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nuvalent has a net margin of 0.00% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
Nuvalent	N/A	-40.11%	-35.43%

Roivant Sciences presently has a consensus target price of $30.55, suggesting a potential upside of 7.01%. Nuvalent has a consensus target price of $137.25, suggesting a potential upside of 37.39%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts plainly believe Nuvalent is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

Roivant Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Roivant Sciences has higher revenue and earnings than Nuvalent. Roivant Sciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	703.38	-$171.98M	-$1.17	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Summary

Nuvalent beats Roivant Sciences on 8 of the 15 factors compared between the two stocks.

How does Nuvalent compare to Moderna?

Nuvalent (NASDAQ:NUVL) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Nuvalent has higher earnings, but lower revenue than Moderna. Nuvalent is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Moderna	$1.94B	9.82	-$2.82B	-$8.15	N/A

In the previous week, Moderna had 3 more articles in the media than Nuvalent. MarketBeat recorded 16 mentions for Moderna and 13 mentions for Nuvalent. Moderna's average media sentiment score of 0.71 beat Nuvalent's score of 0.05 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nuvalent has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Moderna	-143.55%	-26.64%	-19.32%

Nuvalent currently has a consensus price target of $137.25, indicating a potential upside of 37.39%. Moderna has a consensus price target of $35.73, indicating a potential downside of 25.73%. Given Nuvalent's stronger consensus rating and higher probable upside, equities research analysts plainly believe Nuvalent is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Summary

Nuvalent beats Moderna on 8 of the 15 factors compared between the two stocks.

Get Nuvalent News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVL vs. The Competition

Export

Metric	Nuvalent	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.89B	$3.26B	$6.24B	$12.22B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-16.49	18.45	20.66	25.25
Price / Sales	N/A	278.55	546.68	70.71
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	6.26	6.57	9.67	6.63
Net Income	-$425.38M	$24.35M	$3.56B	$335.32M
7 Day Performance	-4.45%	-3.17%	-1.91%	-1.83%
1 Month Performance	-7.16%	-3.55%	-2.65%	-1.16%
1 Year Performance	36.25%	56.89%	31.17%	28.31%

Nuvalent Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVL Nuvalent	2.856 of 5 stars	$99.90 -2.3%	$137.25 +37.4%	+39.5%	$7.89B	N/A	N/A	40
RVMD Revolution Medicines	2.2914 of 5 stars	$147.90 +6.0%	$78.94 -46.6%	+268.4%	$29.65B	$11.58M	N/A	250	Analyst Forecast
INSM Insmed	3.166 of 5 stars	$140.01 +5.1%	$213.23 +52.3%	+60.2%	$28.76B	$606.42M	N/A	1,664
BNTX BioNTech	4.0919 of 5 stars	$99.35 +1.9%	$133.13 +34.0%	-3.5%	$24.67B	$3.25B	N/A	7,807
ROIV Roivant Sciences	2.1545 of 5 stars	$28.36 +1.9%	$30.55 +7.7%	+171.5%	$19.92B	$29.05M	N/A	860	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUVL) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvalent (NUVL) Competitors

NUVL vs. RVMD, INSM, BNTX, ROIV, and MRNA

How does Nuvalent compare to Revolution Medicines?

Summary

How does Nuvalent compare to Insmed?

Summary

How does Nuvalent compare to BioNTech?

Summary

How does Nuvalent compare to Roivant Sciences?

Summary

How does Nuvalent compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVL vs. The Competition

Nuvalent Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvalent (NUVL) Competitors

NUVL vs. RVMD, INSM, BNTX, ROIV, and MRNA

How does Nuvalent compare to Revolution Medicines?

Which has higher valuation and earnings, NUVL or RVMD?

Does the media favor NUVL or RVMD?

Is NUVL or RVMD more profitable?

Do analysts rate NUVL or RVMD?

Do insiders and institutionals have more ownership in NUVL or RVMD?

Which has more risk and volatility, NUVL or RVMD?

Summary

How does Nuvalent compare to Insmed?

Which has more volatility and risk, INSM or NUVL?

Do analysts rate INSM or NUVL?

Does the media favor INSM or NUVL?

Which has preferable earnings & valuation, INSM or NUVL?

Do institutionals & insiders hold more shares of INSM or NUVL?

Is INSM or NUVL more profitable?

Summary

How does Nuvalent compare to BioNTech?

Which has more risk and volatility, NUVL or BNTX?

Do institutionals & insiders have more ownership in NUVL or BNTX?

Do analysts recommend NUVL or BNTX?

Does the media prefer NUVL or BNTX?

Which has stronger valuation & earnings, NUVL or BNTX?

Is NUVL or BNTX more profitable?

Summary

How does Nuvalent compare to Roivant Sciences?

Does the media refer more to ROIV or NUVL?

Do insiders & institutionals hold more shares of ROIV or NUVL?

Is ROIV or NUVL more profitable?

Do analysts recommend ROIV or NUVL?

Which has more volatility and risk, ROIV or NUVL?

Which has preferable valuation and earnings, ROIV or NUVL?

Summary

How does Nuvalent compare to Moderna?

Which has more risk & volatility, NUVL or MRNA?

Which has higher earnings and valuation, NUVL or MRNA?

Does the media prefer NUVL or MRNA?

Do insiders & institutionals have more ownership in NUVL or MRNA?

Is NUVL or MRNA more profitable?

Do analysts rate NUVL or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVL vs. The Competition

Nuvalent Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools